Other safety alerts
|
| |
| China: CFDA alerts public to the cardiovascular risk caused by testosterone |
| |
In Hong Kong, there are seven registered pharmaceutical products containing testosterone, and are prescription only medicines. News on the cardiovascular risk of testosterone was previously issued by the US FDA, EMA, Health Canada, etc, and was posted on the Drug Office website in 2014 and 2015. Letters to inform local healthcare professionals were issued on 16 July 2014 and 13 October 2014.
So far, the Department of Health (DH) has received one case of adverse drug reaction in connection with testosterone which was not related to cardiovascular adverse effect.
On 17 February 2015, the Registration Committee of the Pharmacy and Poisons Board discussed the mater in its meeting, and noted that pharmaceutical products containing testosterone should contain safety information related to cardiovascular risk. The Department of Health (DH) has contacted the relevant registration certificate holders of pharmaceutical products to follow up. DH will continue to remain vigilant on the safety update issued by other overseas drug regulatory authorities regarding testosterone.
Please refer to the following Chinese website for details:
http://www.drugoffice.gov.hk/eps/news/../27354.html
Ends/Saturday, December 31, 2016
Issued at HKT 12:00
|
| |
|
